Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4966914 | 1.00 | EPHX2 (0.33) | EPHX2BDKRB1HDAC4POLBCYP1A2 | |
| SCHEMBL4967016 | 0.90 | BDKRB1 (0.31) | EPHX2BDKRB1HDAC4 | |
| SCHEMBL4967009 | 0.90 | BDKRB1 (0.31) | EPHX2BDKRB1HDAC4 | |
| SCHEMBL4967035 | 0.86 | PDK2 (0.37) | EPHX2HDAC4POLBMEN1KMT2A | |
| SCHEMBL14263248 | 0.86 | PDK2 (0.37) | EPHX2HDAC4POLBMEN1KMT2A | |
| SCHEMBL4966757 | 0.86 | PDK2 (0.37) | EPHX2HDAC4POLBMEN1KMT2A | |
| SCHEMBL4969666 | 0.80 | EPHX2 (0.41) | EPHX2BDKRB1HDAC4POLBMEN1 | |
| SCHEMBL14263249 | 0.77 | HDAC1 (0.41) | EPHX2MEN1KMT2A | |
| SCHEMBL4967413 | 0.77 | HDAC1 (0.41) | EPHX2MEN1KMT2A | |
| SCHEMBL4967406 | 0.77 | HDAC1 (0.41) | EPHX2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963287-A1 | GLUCOCORTICOID RECEPTOR MODULATORS AS ANTIINFLAMMATORY AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-03 | — | — | EP | claimed |
| US-7348322-B2 | Glucocorticoid receptor modulators as antiinflammatory agents | ROCHE PALO ALTO LLC (US) | 2008-03-25 | — | — | US | claimed |
| US-20070135427-A1 | Glucocorticoid receptor modulators as antiinflammatory agents | ROCHE PALO ALTO LLC | 2007-06-14 | — | — | US | claimed |
| WO-2007065828-A1 | GLUCOCORTICOID RECEPTOR MODULATORS AS ANTIINFLAMMATORY AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135427-A1 | Glucocorticoid receptor modulators as antiinflammatory agents | NR3C1, MC2R, NR3C2 | EPHX2 1311/4885BDKRB1 83/4885HDAC4 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.